AACR Virtual Meeting: COVID-19 and Cancer Nancy E. Davidson, MD, of Fred Hutchinson Cancer Research Center, talks about a panel she moderated in which speakers discussed the importance of communicating with patients to ease their concerns about cancer care during the COVID-19 pandemic, allocating protective gear for the most vulnerable patients, increasing telehealth…
There is much debate about the necessity of treating women with ductal carcinoma in situ (DCIS) with surgery or radiotherapy. 1,2 It is disconcerting to…
Can a novel artificial intelligence (AI) model accurately predict how patients with cancer will respond to certain cancer drugs? A recent study investigated.
Sophia McKinley, MD, EdM, of Massachusetts General Hospital, discusses patterns of recurrence in patients with resected cutaneous melanoma during or after adjuvant immunotherapy. She identifies…
In a prospective cohort study, among patients hospitalized due to COVID-19 infection, those receiving cancer treatment had a higher rate of in-hospital mortality vs those…
Recently, the FDA approved pegulicianine (Lumisight) for adult patients with breast cancer to assist in the intraoperative detection of cancerous tissue within the resection cavity…
Sophia McKinley, MD, EdM, of Massachusetts General Hospital, discusses patterns of recurrence in patients with resected cutaneous melanoma during or after adjuvant immunotherapy. She identifies…
The FDA approved lutetium Lu-177 dotatate (Lutathera) for pediatric patients aged 12 years and older with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)—includi…
On April 23, the FDA granted accelerated approval to the type II RAF inhibitor tovorafenib (Ojemda) for patients 6 months of age and older with…
Wendy Vogel, MSN, FNP, AOCNP, FAPO, of the Advanced Practitioner Society for Hematology and Oncology, summarizes a panel discussion in which she took part, on…
In a phase II study reported in the Journal of Clinical Oncology, Barker et al found that induction treatment with vismodegib followed by concurrent treatment…
